PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 3594375

Primary renal lymphoma. Does it exist?

L B Kandel·D L McCullough·L H Harrison·R D Woodruff·E T Ahl·H A Munitz
View original source ↗Export metadata ↓

Abstract

Although secondary renal involvement from systemic lymphoma is common, primary lymphoma of the kidney is not well recognized. One case is reported and 27 cases purported to be primary tumors are reviewed. From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a primary lesion; almost all patients with primary renal lymphoma will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.

Explore related subjects

AngiographyHumansKidney NeoplasmsLymphomaMaleMiddle AgedPrognosisTomography, X-Ray ComputedCase ReportsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L B Kandel, D L McCullough, L H Harrison, R D Woodruff, E T Ahl, H A Munitz. 1987-08-01. Primary renal lymphoma. Does it exist?. https://doi.org/10.1002/1097-0142(19870801)60%3A3%3C386%3A%3Aaid-cncr2820600317%3E3.0.co%3B2-4

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2004

COX-2-selective inhibitor, etodolac, suppresses choroidal neovascularization in a mice model.

Cyclooxygenases (COXs) are involved in choroidal neovascularization (CNV). However, the relative contribution of COX-1 and -2 to CNV has not been determined. In this study, the expression of COX-2 was investigated in CNVs in a murine laser-induced model. Subsequently, we found that experimental CNV expressed COX-2, most remarkably around the highly vascularized lesions. To examine the effect of COX-2 inhibition on CNV, etodolac, a non-steroidal anti-inflammatory drug with a high COX-2 selectivity, was tested on murine CNV model. The results demonstrated that the intensity of fluorescein leakage from the photocoagulated lesions decreased significantly compared to the control eyes following etodolac administration. The area of CNV lesions, as examined using histological sections and choroidal flatmounts at day 7, demonstrated that the average size of the CNV lesions was significantly reduced in the etodolac-treated eyes compared to the control eyes. Together, our results demonstrated that selective COX-2 inhibition suppresses CNV.

Angiography↗